scispace - formally typeset
A

Andrea Garascia

Publications -  61
Citations -  656

Andrea Garascia is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 33 publications receiving 345 citations.

Papers
More filters
Journal ArticleDOI

Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis.

TL;DR: From a functional viewpoint, patients with FM have a more severely impaired LVEF at admission that, despite steep improvement during hospitalization, remains lower than that in patients with NFM at long-term follow-up, which holds true when only the viral forms are considered.
Journal ArticleDOI

Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction

TL;DR: This international registry confirms that patients with FM have higher rates of cardiac death and heart transplantation both in the short- and long-term compared with patients with NFM, and provides evidence that the histologic subtype of FM carries independent prognostic value, highlighting the need for timely endomyocardial biopsy in this condition.
Journal ArticleDOI

Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment.

TL;DR: The clinical features of acute myocarditis are reviewed, including its fulminant presentation, and a pragmatic approach to the diagnosis and treatment is presented, considering indications of American and European Scientific Statements and recent data derived by large contemporary registries.
Journal ArticleDOI

Update on acute myocarditis

TL;DR: A risk-based approach should be promoted in order to identify the most severe AM cases requiring appropriate bundles of care, including early recognition, transfer to tertiary centers, aggressive circulatory supports with inotropes and mechanical devices, histologic confirmation and eventual immunosuppressive therapy.
Journal ArticleDOI

Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial.

TL;DR: This was a multicenter phase II study, including 24 consecutive patients treated with low‐moderate epinephrine doses, whose refractory CS prompted implantation of intra‐aortic balloon pump (IABP) which was subsequently upgraded with peripheral venoarterial extracorporeal membrane oxygenation.